Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC

There is a lack of effective programmed cell death protein 1 (PD-1)‐targeted immunotherapy with good tolerability in patients with advanced hepatocellular carcinoma (HCC) and severely compromised liver function. We assessed patient outcomes after combined camrelizumab and molecular targeted therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ting, Guo, Jiang, Liu, Yushen, Du, Zhaoqing, Guo, Zhaoyang, Fan, Yangwei, Cheng, Long, Zhang, Yue, Gao, Xu, Zhao, Yunyu, He, Xinyuan, Wu, Wenhua, Gao, Ning, Wu, Yinying, Li, Jie, Zhang, Yu, Kang, Wen, Cai, Zhifang, Wang, Wenjun, Li, Xiaopeng, Zan, Ying, Nguyen, Mindie H., Ji, Fanpu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264531/
https://www.ncbi.nlm.nih.gov/pubmed/36840762
http://dx.doi.org/10.1007/s00262-023-03404-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264531/
https://www.ncbi.nlm.nih.gov/pubmed/36840762
http://dx.doi.org/10.1007/s00262-023-03404-8

Ejemplares similares